Clinical Trials Directory

Trials / Completed

CompletedNCT03287830

Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine

Flu2Text: A Multi-Site Study Assessing Text Message Reminders for 2nd Dose of Influenza Vaccine

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
2,105 (actual)
Sponsor
Columbia University · Academic / Other
Sex
All
Age
6 Months – 8 Years
Healthy volunteers
Not accepted

Summary

This multi-site study assesses the impact of text message reminders on the receipt of the second dose of influenza vaccine, and takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) network.

Detailed description

The study is to be conducted over the 1st season (September 2017-April 2018) as an effectiveness trial and the 2nd (September 2018-April 2019) as a replication study. This approach tests that the intervention effects can be replicated across seasons, during which the severity and incidence of influenza disease may vary. Eligible parents will have a child who received his/her first vaccine dose and is in need of 2 doses that season. Current recommendations require 2 doses for certain children 6 months through 8 years old. Within each practice site, parents will be randomized to receive either: 1) text message reminders embedded with influenza vaccine health-literacy promoting information, or 2) usual care. Randomization is to be stratified by practice site, age (6-23 months, 2-8 years) and language (Spanish, English).

Conditions

Interventions

TypeNameDescription
BEHAVIORALText message influenza vaccine remindersText message reminders for second dose of influenza vaccination

Timeline

Start date
2017-10-06
Primary completion
2019-04-30
Completion
2019-04-30
First posted
2017-09-19
Last updated
2023-09-15
Results posted
2023-03-14

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT03287830. Inclusion in this directory is not an endorsement.

Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine (NCT03287830) · Clinical Trials Directory